# TRL for drug development in India: what each level means, from target to DCGI approval

URL: https://zernyxhub.com/blog/trl-drug-development
Author: Dr. Abhay Tharmatt, Research Scientist, R&D, Zernyx Innovations
Published: 2026-10-25
Category: Technology readiness

> TRL for drug development in India: BIRAC's TRL 1 to 9 for drugs, the evidence each level needs, where clinical trials fit and the TRL that DBT expects.

**Short answer:** For drugs, India's BIRAC scale ties each technology readiness level to a stage of drug development. TRL 3 is initial proof of concept in vitro and in limited in vivo studies, TRL 4 is efficacy and safety in a defined animal disease model, TRL 5 is GLP preclinical data enough to seek DCGI permission for clinical trials, and TRLs 6 to 8 follow Phase I, Phase II and Phase III. TRL 9 is commercial launch with post-marketing studies.

Drug researchers often find TRL frustrating at first. The scale began with hardware: breadboards, prototypes, systems tested in the field. A small-molecule candidate or a new formulation does not have a breadboard. Yet Indian funders, incubators and investors increasingly ask for a TRL, and they expect the number to mean something.

It does mean something, once you use a scale written for drugs. This guide walks through the drug TRL definitions used by BIRAC, what evidence each level needs, where clinical trials fit, and what level DBT expects for drug projects. It is written for researchers and early-stage startups preparing a proposal or a pitch.

## The short answer

On BIRAC's scale for drugs, **TRL 3** is initial proof of concept in vitro and in limited in vivo studies. **TRL 4** is efficacy and safety of the candidate formulation in a **defined animal disease model**. **TRL 5** is GLP preclinical data strong enough to apply to the **DCGI** for clinical trials. **TRLs 6, 7 and 8** follow **Phase I, Phase II and Phase III**, and **TRL 9** is commercial launch with post-marketing studies. DBT's published guidance lists **TRL 4** as the required level for drug projects.

## Why drugs need their own TRL scale

The general nine-level scale describes components, prototypes and systems. Drug development moves through different gates: target and hypothesis, in vitro work, animal studies, regulatory toxicology, then human trials in phases. These gates are set by regulators, so readiness is tied to regulatory evidence.

The Biotechnology Industry Research Assistance Council (BIRAC) adapted the scale for this reason. It publishes separate TRL definitions for areas including drugs, vaccines, biosimilars, medical devices and diagnostics. In India, clinical trials of new drugs are governed by the New Drugs and Clinical Trials Rules, 2019, administered by the Central Drugs Standard Control Organisation, which is headed by the Drugs Controller General of India (DCGI). BIRAC's drug levels refer to DCGI approvals at the later stages.

## TRL 1 to 9 for a drug, level by level

Here is BIRAC's drug scale (drugs including drug delivery), in summary:

- **TRL 1, Ideation.** A need is identified, and basic principles are observed and reported.
- **TRL 2, Proof of principle.** Hypotheses and protocols are developed, supported by early in vitro work such as biochemical studies.
- **TRL 3, Proof of concept demonstrated.** Hypotheses are tested, with initial proof of concept in a limited number of in vitro models and limited in vivo efficacy studies.
- **TRL 4, Proof of concept established.** Efficacy and safety of the candidate formulation are shown in a defined animal disease model, with formulation, pharmacokinetic, ADME and pharmacodynamic results and preliminary safety data.
- **TRL 5, Early stage validation.** Preclinical studies, including GLP efficacy and acute and chronic toxicity in animals, give enough data to apply to the DCGI for clinical trials, and Phase I is approved.
- **TRL 6.** Material is produced under the required quality conditions for trials, Phase I is completed and its results submitted, and approval for Phase II is sought.
- **TRL 7, Advanced stage validation.** Phase II is completed, the DCGI reviews the data, and the Phase III plan is approved.
- **TRL 8, Pre-commercialisation.** Phase III is completed, the DCGI approves the new drug application, and a manufacturing licence is granted.
- **TRL 9, Commercialisation.** The drug is launched, with post-marketing studies and surveillance.

**BIRAC's TRL scale for drugs, in short**
- TRL 1: Need identified, principles observed
- TRL 2: Hypothesis, early in vitro support
- TRL 3: In vitro and limited in vivo proof
- TRL 4: Efficacy and safety in animal model
- TRL 5: GLP data, apply to DCGI for trials
- TRL 6: Phase I completed
- TRL 7: Phase II completed
- TRL 8: Phase III, NDA approved
- TRL 9: Launched, post-marketing studies
(Most academic projects: TRL 3 to TRL 5)

Most academic drug projects in India sit between TRL 3 and TRL 5. Moving from TRL 3 to TRL 4 is the step funders watch most closely, because it is where a promising in vitro result either holds up in a disease model or does not. Our guide to [moving from TRL 3 to TRL 4](https://zernyxhub.com/blog/trl-3-to-trl-4) covers that step in general terms.

## What evidence each early level needs

A TRL claim is only as strong as the evidence behind it. For the levels most researchers deal with:

**TRL 3.** In vitro data on the mechanism or activity, ideally in more than one model, and some early in vivo efficacy. Show the assays, the controls and the reproducibility.

**TRL 4.** A defined animal disease model with efficacy and safety of the candidate formulation. Include formulation data, pharmacokinetics, ADME, pharmacodynamics and preliminary safety. A single in vivo experiment with one dose rarely carries a TRL 4 claim on its own.

**TRL 5.** GLP-compliant preclinical studies, including efficacy and acute and chronic toxicity, at the level needed for a clinical trial application to the DCGI. This is where academic labs usually need a contract research partner, because GLP studies need an accredited facility.

Our post on [what evidence proves a TRL](https://zernyxhub.com/blog/trl-evidence) explains how to present this in a proposal.

## Where clinical trials sit on other scales

Not every scale places the milestones in the same spot. The US Congressionally Directed Medical Research Programs' biomedical product guidelines, for example, use one table for drugs, biologics and devices. In that table, completing GLP studies, producing GMP batches and getting approval to begin human studies falls at TRL 5, Phase I at TRL 6, and both Phase II and Phase III at TRL 7, with marketing approval at TRL 8.

**Where trial phases sit on two drug TRL scales**
BIRAC (India):
- TRL 5: GLP data, DCGI trial approval
- TRL 6: Phase I completed
- TRL 7: Phase II completed
- TRL 8: Phase III, NDA approved
US CDMRP guidelines:
- TRL 5: GLP, GMP batches, human studies approved
- TRL 6: Phase I
- TRL 7: Phase II and Phase III
- TRL 8: marketing approval
Name the scale you used in every proposal.

The differences look small, but they matter when you report a TRL to an Indian funder and a foreign partner at the same time. India's National Technology Readiness Assessment Framework (NTRAF), unveiled in December 2025, also has a pharma annex. Its examples for the later levels are close to BIRAC's, with Phase II at TRL 7 and NDA approval at TRL 8. Our post on [moving from TRL 6 to TRL 9](https://zernyxhub.com/blog/trl-6-to-trl-9) covers those later stages.

## What TRL Indian funders expect for drug projects

DBT publishes TRL guidance that lists a required level for each application area. For **drugs, including drug delivery**, it lists **TRL 4, proof of concept established**: formulation studies, preliminary PK, ADME and PD, preliminary safety, and efficacy in an in vivo disease model. For **clinical trial** projects, it lists **TRL 5**, with GLP-level preclinical efficacy and toxicity data enough for a regulatory application for clinical trials.

Calls change, and each scheme can set its own requirement, so always read the current call. But the message is clear: a drug project at TRL 3 with in vitro data alone will struggle where TRL 4 is expected.

## Common mistakes

- **Using the hardware scale for a drug.** Words like "prototype" and "system" do not map to drug development. Use the drug scale your funder uses.
- **Claiming TRL 4 on one animal study.** TRL 4 needs a defined disease model plus formulation, PK, ADME, PD and preliminary safety.
- **Calling non-GLP toxicity "regulatory ready".** TRL 5 needs GLP-level studies.
- **Not naming the scale.** BIRAC, NTRAF and foreign scales place some milestones differently.
- **Ignoring manufacturing readiness.** A molecule at TRL 5 still needs material made under the right quality conditions for trials. Our post on [MRL vs TRL](https://zernyxhub.com/blog/mrl-vs-trl) explains why both matter.

## Checking where your drug project stands

It helps to put your evidence through a structured assessment before a funder or investor does. TRL Pro gives you a structured TRL 1 to 9 assessment of your project, using Zernyx's own copyrighted framework (ZTRAF), which covers more than 60 technology domains and subdomains. You can [assess your project with TRL Pro](https://app.zernyxhub.com/trl-calculator) and use the result to plan the studies that move you up a level.

## FAQ

### What TRL is a drug candidate at proof of concept in animals?

On BIRAC's drug scale, efficacy and safety of the candidate formulation in a defined animal disease model, with formulation, PK, ADME, PD and preliminary safety data, is TRL 4.

### At what TRL does a drug enter clinical trials?

On BIRAC's scale, TRL 5 is reached when GLP preclinical data are enough to apply to the DCGI for clinical trials. Phase I is completed at TRL 6. Other scales place these milestones slightly differently.

### What TRL does DBT expect for drug projects?

DBT's published guidance lists TRL 4 for drugs, including drug delivery, and TRL 5 for clinical trial projects. Check the specific call, because requirements vary by scheme.

### Is a new formulation of a known drug assessed on the same scale?

BIRAC's drug scale includes drug delivery, so formulations are assessed on it too, with evidence matched to each level.

---

Published by Zernyx Hub. More: https://zernyxhub.com/llms.txt
